BIJHANS.BO · BSE
BIJOY HANS LTD.
₹134.05
+4.97% (+₹6.35)
Prev. close
₹127.7
Volume
1,740
As of
BSE · may be slightly delayed · 16:00 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About BIJOY HANS LTD.
Arvaya Healthcare Limited develops and provides a platform that combines hospitals, diagnostics, digital health technology, and wellness services. The company's platform offers an artificial intelligence (AI) health assistant, providing personalized health guidance and proactive recommendations; seamless booking options, such as instant appointments, teleconsultations, and home diagnostic services; real-time tracking, including monitoring vitals, syncing wearables, and tracking health trends; and connected care that enables users to connect with doctors, labs, and pharmacies. Arvaya Healthcare Limited was formerly known as Bijoy Hans Limited and changed its name to Arvaya Healthcare Limited in May 2026. The company was incorporated in 1985 and is based in Miraj, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Kaushal Uttam Shah
Headquarters
Miraj
Website
arvayahealth.comExchange
View on BSE ↗Key stats
Market cap
₹411.16 Cr
P/E ratio (TTM)
570.8
EPS (TTM)
₹0.15
EPS · quarter ended Mar 2026
₹0.26
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.1% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹40.30 L | ₹32.70 L | ₹29.96 L | ₹27.98 L | ₹27.89 L | ₹9.11 Cr |
| EBITDA | ₹-4.51 L | ₹-15.29 L | ₹-38.01 L | ₹-6.31 L | ₹22.48 L | ₹2.12 Cr |
| Net income | ₹-8.90 L | ₹-18.80 L | ₹-44.41 L | ₹-11.72 L | ₹13.61 L | ₹70.24 L |
| Diluted EPS | — | ₹-0.63 | ₹-1.48 | ₹-0.39 | ₹0.45 | — |
Diluted EPS has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹3.63 Cr | ₹3.49 Cr | ₹3.59 Cr | ₹140.62 Cr | |
| Total debt | — | — | ₹7.69 L | ₹6.06 L | ₹0 | ₹49.38 Cr |
| Stockholders' equity | — | — | ₹3.51 Cr | ₹3.39 Cr | ₹3.53 Cr | ₹59.90 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2025-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2025-03-31, 2021-03-31, 2022-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2021-03-31, 2022-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| BIJOY HANS LTD. | ₹411.16 Cr | ₹85.62 | 570.8 | 6.86 | 1.2% | 0.82 | +3167.6% | +178.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.